Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.

[1]  D. Kobayashi,et al.  Survivin mRNA expression in patients with breast cancer. , 2002, Anticancer research.

[2]  E. Felip,et al.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[4]  L K Miller,et al.  An exegesis of IAPs: salvation and surprises from BIR motifs. , 1999, Trends in cell biology.

[5]  A. Davidoff,et al.  The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. , 2001, Journal of pediatric surgery.

[6]  D. Altieri,et al.  Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[7]  H. Idikio.  Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. , 1998, International journal of oncology.

[8]  D. Vaux,et al.  Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs , 2001, Genome Biology.

[9]  A. Markham,et al.  Expression of the antiapoptosis gene,Survivin, predicts death from recurrent colorectal carcinoma , 2000, Gut.

[10]  S. Reed,et al.  Survivin’ cell-separation anxiety , 1999, Nature Cell Biology.

[11]  M. Ikeguchi,et al.  Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. , 2001, International journal of molecular medicine.

[12]  A. Kaider,et al.  Expression of the multidrug resistance protein (MRP1) in breast cancer. , 1999, Anticancer research.

[13]  S. Moriyama,et al.  Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy , 2001, International journal of cancer.

[14]  A. Sandler,et al.  The survivin:Fas ratio is predictive of recurrent disease in neuroblastoma. , 2002, Journal of pediatric surgery.

[15]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[16]  P. Grundy,et al.  The survivin:fas ratio in pediatric renal tumors. , 2001, Journal of pediatric surgery.

[17]  K. Ihara,et al.  Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. , 2001, Cancer letters.

[18]  V. Castronovo,et al.  DECREASED EXPRESSION OF GALECTIN‐3 IS ASSOCIATED WITH PROGRESSION OF HUMAN BREAST CANCER , 1996, The Journal of pathology.

[19]  H. Grabsch,et al.  Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression , 2002, British Journal of Cancer.

[20]  D J Bain,et al.  Role of arteriography in the selection of patients for carotid endarterectomy , 1998, The British journal of surgery.

[21]  C. Kampf,et al.  Increased survivin transcript levels: An independent negative predictor of survival in soft tissue sarcoma patients , 2001, International journal of cancer.

[22]  L. O’Driscoll,et al.  Prognostic importance of survivin in breast cancer , 2003, British Journal of Cancer.

[23]  David L. Page,et al.  Diagnostic Histopathology of the Breast , 1988 .

[24]  A. Venturino,et al.  Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. , 1999, Anticancer research.

[25]  S. Tang,et al.  Expression of BAG-1 in invasive breast carcinomas. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. O’Driscoll,et al.  Survivin: role in normal cells and in pathological conditions. , 2003, Current cancer drug targets.

[27]  D. Altieri,et al.  Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.

[28]  J. McNiff,et al.  Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[29]  B. Dörken,et al.  Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. , 1996, The Journal of clinical investigation.

[30]  C. Suschek,et al.  Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas , 2002, International journal of cancer.

[31]  E Springer,et al.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. , 1999, Cancer research.

[32]  John Calvin Reed,et al.  The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  D. Altieri,et al.  The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.

[34]  R. Kim,et al.  An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery , 2001, Breast cancer.

[35]  Y. Takano,et al.  Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. , 2001, Cancer letters.

[36]  M. Ikeguchi,et al.  survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma , 2002, British Journal of Cancer.